Learn why single-cell technologies are vital for Endometriosis research by watching our webinar
Endometriosis is a debilitating disease that affects 10% of women and girls of reproductive age. There is no cure, no certain cause and no non-invasive method of diagnosing the disease, leading to a reduced quality of life for the patients and a significant socio-economic burden. Join us on our webinar on why single-cell technologies are vital for endometriosis research.
Prof. Dr Michael D. Mueller is an expert in endometriosis and women’s health. The complexity of this disease requires a novel research approach by single-cell analysis. Therefore, Prof. Dr. med. Müller started collaborating with Scailyte AG, the specialist in single-cell analysis. In a joint project, they strive to develop a non-invasive diagnosis method, and potentially a prognostic method to reduce the suffering of endometriosis patients. Prof. Mueller is a renowned gynaecologist and gynaecological oncologist, and managing director of the Women’s Health Clinic at the University Hospital of Bern (Inselspital). He is the founding member and current president of the working group for Endoscopic Gynecology.
Join this webinar with Prof. Mueller, in cooperation with Scailyte, to learn more about “Why single-cell technologies are vital for Endometriosis research.”
Watch the webinar here: https://youtu.be/XPmhGRy-1AY
About Scailyte
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Recent News
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
Recent News
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...
Recent News
Life Science Industry Meets Data Science Symposium
Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Recent News
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
Recent News
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...
Life Science Industry Meets Data Science Symposium
Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...